Wistuba, Ignacio I.

Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients.

Xie, Y., Xiao, G., Coombes, K. R., Behrens, C., Solis, L. M., Raso, G., Girard, L., Erickson, H. S., Roth, J., Heymach, J. V., et al. (2011) · Clinical Cancer Research

Gene expression and cancer classificationLung Cancer Research Studies

Cited by 162

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.

Somaiah, N., Conley, A. P., Parra, E. R., Lin, H., Amini, B., Solis Soto, L., Salazar, R., Barreto, C., Chen, H., Gite, S., et al. (2022) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 159

Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer

Tang, C., Hobbs, B., Amer, A., Li, X., Behrens, C., Canales, J. R., Cuentas, E. P., Villalobos, P., Fried, D., Chang, J. Y., et al. (2018) · Scientific Reports

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 154

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 146

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Nilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 146

Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer

McMillan, E. A., Ryu, M.-J., Diep, C. H., Mendiratta, S., Clemenceau, J. R., Vaden, R. M., Kim, J.-H., Motoyaji, T., Covington, K. R., Peyton, M., et al. (2018) · Cell

Computational Drug Discovery MethodsLung Cancer Treatments and Mutations

Cited by 141

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy

William, W. N., Pataer, A., Kalhor, N., Correa, A. M., Rice, D. C., Wistuba, I. I., Heymach, J., Lee, J. J., Kim, E. S., Munden, R., et al. (2013) · Journal of Thoracic Oncology

Lung Cancer Diagnosis and TreatmentMedical Imaging Techniques and Applications

Cited by 138

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 133

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., Qin, K., Sujit, S. J., Lu, X., Young, E., et al. (2023) · The Lancet Digital Health

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 121

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas

Konstantinidou, G., Ramadori, G., Torti, F., Kangasniemi, K., Ramirez, R. E., Cai, Y., Behrens, C., Dellinger, M. T., Brekken, R. A., Wistuba, I. I., et al. (2013) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 114

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy

Weissferdt, A., Pataer, A., Vaporciyan, A. A., Correa, A. M., Sepesi, B., Moran, C. A., Wistuba, I. I., Roth, J. A., Shewale, J. B., Heymach, J. V., et al. (2020) · Clinical Lung Cancer

Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Cited by 113

Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance

Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 110

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers

Cancer Cells and MetastasisCancer Immunotherapy and Biomarkers

Cited by 103

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

Li, H., Liu, Z., Liu, L., Zhang, H., Han, C., Girard, L., Park, H., Zhang, A., Dong, C., Ye, J., et al. (2022) · Cell Reports Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 102

PI4KIIIβ is a therapeutic target in chromosome 1q–amplified lung adenocarcinoma

Tan, X., Banerjee, P., Pham, E. A., Rutaganira, F. U. N., Basu, K., Bota-Rabassedas, N., Guo, H.-F., Grzeskowiak, C. L., Liu, X., Yu, J., et al. (2020) · Science Translational Medicine

Cellular transport and secretionCancer, Lipids, and Metabolism

Cited by 70

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 53

A Search for Novel Cancer/Testis Antigens in Lung Cancer Identifies VCX/Y Genes, Expanding the Repertoire of Potential Immunotherapeutic Targets

Taguchi, A., Taylor, A. D., Rodriguez, J., Çeliktaş, M., Liu, H., Ma, X., Zhang, Q., Wong, C.-H., Chin, A., Girard, L., et al. (2014) · Cancer Research

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 53

Development and validation of a gene signature classifier for consensus molecular subtyping of colorectal carcinoma in a CLIA-certified setting

Morris, J. S., Luthra, R., Liu, Y., Duose, D. Y., Lee, W., Reddy, N. G., Windham, J., Chen, H., Tong, Z., Zhang, B., et al. (2021) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 36

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer

Cascone, T., Gold, K. A., Swisher, S. G., Liu, D. D., Fossella, F. V., Sepesi, B., Pataer, A., Weissferdt, A., Kalhor, N., Vaporciyan, A. A., et al. (2018) · The Annals of Thoracic Surgery

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 32

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., et al. (2020) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 31

The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells

Bommi, P. V., Bowen, C. M., Reyes-Uribe, L., Wu, W., Katayama, H., Rocha, P., Parra, E. R., Francisco-Cruz, A., Ozcan, Z., Tosti, E., et al. (2021) · Cancer Research

Genetic factors in colorectal cancerDNA Repair Mechanisms

Cited by 10

Data from The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells

Bommi, P. V., Bowen, C. M., Reyes-Uribe, L., Wu, W., Katayama, H., Rocha, P., Parra, E. R., Francisco-Cruz, A., Ozcan, Z., Tosti, E., et al. (2023)

Genetic factors in colorectal cancerDNA Repair Mechanisms

Cited by 0